Iain C Macdougall

List of Publications by Citations

229 papers	11,741 citations	58 h-index	103 g-index
252 ext. papers	13,730 ext. citations	7.4 avg, IF	6.59 L-index

#	Paper	IF	Citations
229	Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *New England Journal of Medicine*, **2006**, 355, 2071-84	59.2	1576
228	Iron deficiency anaemia. *Lancet, The*, **2016**, 387, 907-16	40	611
227	Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. *Journal of the American Society of Nephrology: JASN*, **1999**, 10, 2392-5	12.7	337
226	A randomized controlled study of iron supplementation in patients treated with erythropoietin. *Kidney International*, **1996**, 50, 1694-9	9.9	280
225	Hemoglobin variability does not predict mortality in European hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1765-75	12.7	262
224	Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 11, 39-43	4.3	245
223	Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. *European Heart Journal*, **2013**, 34, 816-29	9.5	230
222	Guideline for the laboratory diagnosis of functional iron deficiency. *British Journal of Haematology*, **2013**, 161, 639-48	4.5	209
221	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. *New England Journal of Medicine*, **2019**, 380, 447-458	59.2	187
220	Erythropoietins: a common mechanism of action. *Experimental Hematology*, **2008**, 36, 1573-84	3.1	181
219	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. *Circulation*, **2017**, 136, 1374-1383	16.7	179
218	FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. *Nephrology Dialysis Transplantation*, **2014**, 29, 2075-84	4.3	173
217	Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. *Kidney International*, **2017**, 92, 47-66	9.9	168
216	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. *American Journal of Hematology*, **2017**, 92, 1068-1078	7.1	168
215	Iron status in patients with chronic heart failure. *European Heart Journal*, **2013**, 34, 827-34	9.5	154
214	Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 1211-5	6.9	153
213	Intravenous iron sucrose: establishing a safe dose. *American Journal of Kidney Diseases*, **2001**, 38, 988-91	7.4	145

212	The inflammatory response and epoetin sensitivity. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 1, 48-52	4.3	140
211	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. *Nature Reviews Cardiology*, **2011**, 8, 485-93	14.8	132
210	Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. *Pharmaceutical Research*, **2012**, 29, 1454-67	4.5	131
209	A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. *New England Journal of Medicine*, **2009**, 361, 1848-55	59.2	126
208	Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. *Lancet, The*, **2006**, 368, 947-53	40	123
207	CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. *Psychophysiology*, **2005**, 4, 436-40		114
206	Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. *Lancet, The*, **2004**, 363, 1768-71	40	112
205	Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. *Nephrology Dialysis Transplantation*, **2010**, 25, 2846-50	4.3	110
204	Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1776-84	12.7	106
203	Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial. *American Journal of Kidney Diseases*, **2015**, 65, 425-34	7.4	104
202	Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). *Clinical Pharmacokinetics* , **1991**, 20, 99-113	6.2	102
201	The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. *Nephrology Dialysis Transplantation*, **1999**, 14, 1836-41	4.3	100
200	Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 2651-60	12.7	90
199	Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. *Transplantation*, **2006**, 81, 1112-8	1.8	87
198	Regulatory and clinical considerations for biosimilar oncology drugs. *Lancet Oncology, The*, **2014**, 15, e594-e605	21.7	86
197	Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. *Lancet, The*, **2020**, 396, 1353-1361	40	86
196	Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?. *European Journal of Heart Failure*, **2015**, 17, 248-62	12.3	85
195	Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. *New England Journal of Medicine*, **2013**, 368, 320-32	59.2	85

194	PRE-dialysis survey on anaemia management. *Nephrology Dialysis Transplantation*, **2003**, 18, 89-100	4.3	85
193	Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 5, 66-70	4.3	85
192	Novel erythropoiesis-stimulating agents: a new era in anemia management. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 200-7	6.9	83
191	Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. *American Journal of Nephrology*, **2017**, 45, 187-199	4.6	82
190	C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 337-47	6.9	82
189	Randomized trial of intravenous iron-induced hypophosphatemia. *JCI Insight*, **2018**, 3,	9.9	80
188	Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. *Kidney International*, **2012**, 81, 727-32	9.9	79
187	The available intravenous iron formulations: History, efficacy, and toxicology. *Hemodialysis International*, **2017**, 21 Suppl 1, S83-S92	1.7	77
186	Peginesatide in patients with anemia undergoing hemodialysis. *New England Journal of Medicine*, **2013**, 368, 307-19	59.2	75
185	Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 1877-82	12.7	74
184	Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. *American Journal of Hematology*, **2018**, 93, 683-690	7.1	70
183	A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 705-12	6.9	70
182	Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. *American Journal of Kidney Diseases*, **2010**, 55, 69-76	7.4	69
181	Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?. *Nephrology Dialysis Transplantation*, **2004**, 19, 288-93	4.3	68
180	Pure red cell aplasia induced by erythropoiesis-stimulating agents. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 193-9	6.9	67
179	Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. *Nephrology Dialysis Transplantation*, **2010**, 25, 4009-17	4.3	64
178	Iron and the anaemia of chronic disease: a review and strategic recommendations. *Current Medical Research and Opinion*, **2006**, 22, 731-7	2.5	64
177	The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. *European Journal of Heart Failure*, **2015**, 17, 329-39	12.3	62

176	Aerobic or Resistance Training and Pulse Wave Velocity in Kidney Transplant Recipients: A 12-Week Pilot Randomized Controlled Trial (the Exercise in Renal Transplant [ExeRT] Trial). *American Journal of Kidney Diseases*, **2015**, 66, 689-98	7.4	61
175	An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). *Nephrology Dialysis Transplantation*, **2001**, 16 Suppl 3, 14-21	4.3	61
174	Current status of the measurement of blood hepcidin levels in chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 1681-9	6.9	59
173	Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. *Advances in Chronic Kidney Disease*, **2009**, 16, 117-30	4.7	59
172	Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). *Nephrology Dialysis Transplantation*, **2015**, 30, 451-60	4.3	57
171	Effect of red cell transfusions on future kidney transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 852-60	6.9	55
170	Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. *European Journal of Heart Failure*, **2012**, 14, 882-6	12.3	54
169	Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. *Nephrology Dialysis Transplantation*, **2005**, 20 Suppl 4, iv9-15	4.3	54
168	Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. *American Journal of Kidney Diseases*, **2005**, 46, 283-9	7.4	53
167	Safety of intravenous iron formulations: facts and folklore. *Blood Transfusion*, **2014**, 12, 296-300	3.6	52
166	Effects of Molidustat in the Treatment of Anemia in CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 28-39	6.9	51
165	A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2015**, 30, 1577-89	4.3	49
164	Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?. *Current Medical Research and Opinion*, **2010**, 26, 473-82	2.5	49
163	A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2008**, 23, 263-8	4.3	49
162	IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 7083-7088	11.5	48
161	Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. *American Journal of Kidney Diseases*, **1999**, 34, s40-s46	7.4	47
160	Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. *Nephrology Dialysis Transplantation*, **2003**, 18, 576-81	4.3	46
159	Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?. *American Journal of Nephrology*, **2018**, 47, 72-83	4.6	45

158	New anemia therapies: translating novel strategies from bench to bedside. *American Journal of Kidney Diseases*, **2012**, 59, 444-51	7.4	43
157	Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 845-55	6.9	43
156	Vascular access for hemodialysis in the elderly. *Journal of Vascular Surgery*, **2011**, 53, 1039-43	3.5	42
155	Recent advances in erythropoietic agents in renal anemia. *Seminars in Nephrology*, **2006**, 26, 313-8	4.8	38
154	Laparoscopic sleeve gastrectomy is a novel and effective treatment for obesity in patients with chronic kidney disease. *Obesity Surgery*, **2012**, 22, 119-23	3.7	37
153	Use of intravenous iron supplementation in chronic kidney disease: an update. *Iranian Journal of Kidney Diseases*, **2013**, 7, 9-22	0.9	37
152	How important is transfusion avoidance in 2013?. *Nephrology Dialysis Transplantation*, **2013**, 28, 1092-9	4.3	36
151	Evolution of iv iron compounds over the last century. *Journal of Renal Care*, **2009**, 35 Suppl 2, 8-13	1.6	35
150	Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. *Nephrology Dialysis Transplantation*, **2007**, 22, 784-93	4.3	35
149	Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions. *CKJ: Clinical Kidney Journal*, **2017**, 10, i16-i24	4.5	34
148	On the safety of intravenous iron, evidence trumps conjecture. *Haematologica*, **2015**, 100, e214-5	6.6	34
147	Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 1176-82	6.9	34
146	Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. *Current Medical Research and Opinion*, **2004**, 20, 83-6	2.5	34
145	Intravenous administration of iron in epoetin-treated haemodialysis patients--which drugs, which regimen?. *Nephrology Dialysis Transplantation*, **2000**, 15, 1743-5	4.3	34
144	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 1118-1127	12.7	33
143	Exercise therapy in individuals with chronic kidney disease: a systematic review and synthesis of the research evidence. *Annual Review of Nursing Research*, **2013**, 31, 235-75	0.7	31
142	Mortality and morbidity following exercise-based renal rehabilitation in patients with chronic kidney disease: the effect of programme completion and change in exercise capacity. *Nephrology Dialysis Transplantation*, **2019**, 34, 618-625	4.3	31
141	Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. *Nephrology Dialysis Transplantation*, **2017**, 32, 1530-1539	4.3	30

140	Psychosocial and Clinical Correlates of Fatigue in Haemodialysis Patients: the Importance of Patients' Illness Cognitions and Behaviours. *International Journal of Behavioral Medicine*, **2016**, 23, 271-281	2.6	30
139	A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). *Seminars in Thrombosis and Hemostasis*, **2012**, 38, 783-96	5.3	30
138	Predialysis Survey on Anemia Management: patient referral. *American Journal of Kidney Diseases*, **2003**, 41, 49-61	7.4	30
137	Intravenous iron: a framework for changing the management of iron deficiency. *Lancet Haematology,the*, **2020**, 7, e342-e350	14.6	28
136	Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. *Nephrology Dialysis Transplantation*, **2006**, 21, 2963-5	4.3	28
135	The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. *Nephrology Dialysis Transplantation*, **2014**, 29, 843-50	4.3	27
134	Darbepoetin alfa: a new therapeutic agent for renal anemia. *Kidney International*, **2002**, 55-61	9.9	27
133	Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. *American Journal of Nephrology*, **2019**, 49, 271-280	4.6	26
132	Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. *Expert Opinion on Drug Safety*, **2016**, 15, 1421-6	4.1	26
131	The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review. *CKJ: Clinical Kidney Journal*, **2017**, 10, 79-88	4.5	26
130	Pharmacology of darbepoetin alfa. *Nephrology Dialysis Transplantation*, **2007**, 22 Suppl 4, iv2-iv9	4.3	26
129	Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). *Journal of General Internal Medicine*, **2012**, 27, 1697-703	4	25
128	Neutrophil gelatinase-associated lipocalin and hepcidin: what do they have in common and is there a potential interaction?. *Kidney and Blood Pressure Research*, **2010**, 33, 157-65	3.1	25
127	Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2579-86	6.9	24
126	Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial. *BMC Nephrology*, **2016**, 17, 177	2.7	22
125	Weight loss, adipokines, and quality of life after sleeve gastrectomy in obese patients with stages 3-4 CKD: a randomized controlled pilot study. *American Journal of Kidney Diseases*, **2014**, 64, 660-3	7.4	22
124	Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial. *Journal of Cachexia, Sarcopenia and Muscle*, **2013**, 4, 247-57	10.3	22
123	New options for the anemia of chronic kidney disease. *Kidney International Supplements*, **2017**, 7, 157-163	3.3	22

122	Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?. *Nephrology Dialysis Transplantation*, **2004**, 19 Suppl 5, V73-78	4.3	22
121	Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. *PLoS ONE*, **2016**, 11, e0157063	3.7	22
120	Iron supplementation in nephrology and oncology: what do we have in common?. *Oncologist*, **2011**, 16 Suppl 3, 25-34	5.7	21
119	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. *American Journal of Nephrology*, **2018**, 48, 260-268	4.6	21
118	Risk for chronic kidney disease increases with obesity: Health Survey for England 2010. *Public Health Nutrition*, **2015**, 18, 3349-54	3.3	20
117	Serum hemojuvelin and hepcidin levels in chronic kidney disease. *American Journal of Nephrology*, **2012**, 35, 295-304	4.6	20
116	Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease. *American Journal of Hypertension*, **2012**, 25, 1024-9	2.3	20
115	Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe?. *Nephrology Dialysis Transplantation*, **2007**, 22, 2738-42	4.3	20
114	Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. *Nephrology*, **2017**, 22, 969-976	2.2	19
113	A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. *Nephrology Dialysis Transplantation*, **2018**, 33, 1628-1635	4.3	19
112	The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. *American Journal of Kidney Diseases*, **2005**, 45, 381-7	7.4	19
111	Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients. *PLoS ONE*, **2016**, 11, e0148938	3.7	19
110	Long-term pulse wave velocity outcomes with aerobic and resistance training in kidney transplant recipients - A pilot randomised controlled trial. *PLoS ONE*, **2017**, 12, e0171063	3.7	19
109	Rheological studies during treatment of renal anaemia with recombinant human erythropoietin. *British Journal of Haematology*, **1991**, 77, 550-8	4.5	18
108	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. *Kidney International*, **2021**, 99, 1280-1295	9.9	18
107	Measuring fatigue in haemodialysis patients: The factor structure of the Chalder Fatigue Questionnaire (CFQ). *Journal of Psychosomatic Research*, **2016**, 84, 81-83	4.1	18
106	Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease. *Nephron*, **2019**, 143, 243-254	3.3	17
105	Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study. *Pharmacoepidemiology and Drug Safety*, **2015**, 24, 414-26	2.6	17

104	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. *Nephrology Dialysis Transplantation*, **2012**, 27, 3923-9	4.3	16
103	Iron deficiency: what are the future trends in diagnostics and therapeutics?. *Clinical Chemistry*, **2013**, 59, 740-5	5.5	16
102	Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production. *Nephrology Dialysis Transplantation*, **2003**, 18, 133-40	4.3	16
101	Treatment of renal anemia with recombinant human erythropoietin. *Current Opinion in Nephrology and Hypertension*, **1992**, 1, 210-9	3.5	16
100	HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. *Pediatric Nephrology*, **2019**, 34, 365-378	3.2	16
99	Examining the efficacy of social-psychological interventions for the management of fatigue in end-stage kidney disease (ESKD): a systematic review with meta-analysis. *Health Psychology Review*, **2017**, 11, 197-216	7.1	15
98	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. *New England Journal of Medicine*, **2021**,	59.2	15
97	Measurement of hepcidin isoforms in human serum by liquid chromatography with high resolution mass spectrometry. *Bioanalysis*, **2017**, 9, 541-553	2.1	14
96	An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. *Journal of Medical Economics*, **2013**, 16, 108-14	2.4	14
95	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. *New England Journal of Medicine*, **2021**,	59.2	14
94	Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk. *Kidney Medicine*, **2020**, 2, 341-353	2.8	14
93	Participation in a Structured Weight Loss Program and All-Cause Mortality and Cardiovascular Morbidity in Obese Patients With Chronic Kidney Disease. *Journal of Renal Nutrition*, **2015**, 25, 472-9	3	13
92	'It's when you're not doing too much you feel tired': A qualitative exploration of fatigue in end-stage kidney disease. *British Journal of Health Psychology*, **2018**, 23, 311-333	8.3	13
91	Fatigue in Prevalent Haemodialysis Patients Predicts All-cause Mortality and Kidney Transplantation. *Annals of Behavioral Medicine*, **2019**, 53, 501-514	4.5	13
90	Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin. *Nephrology Dialysis Transplantation*, **2012**, 27, 50-7	4.3	13
89	Once-weekly erythropoietic therapy: is there a difference between the available preparations?. *Nephrology Dialysis Transplantation*, **2002**, 17, 2047-51	4.3	13
88	Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. *Current Opinion in Investigational Drugs*, **2008**, 9, 1034-47		13
87	Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial?. *Clinical Nephrology*, **2017**, 88, 301-310	2.1	12

86	Epoetin-induced pure red cell aplasia: diagnosis and treatment. *Current Opinion in Nephrology and Hypertension*, **2007**, 16, 585-8	3.5	12
85	Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?. *Nephrology Dialysis Transplantation*, **2004**, 19, 2901-5	4.3	12
84	Ace inhibitors and erythropoietin responsiveness. *American Journal of Kidney Diseases*, **2001**, 38, 649-51	7.4	12
83	Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. *BMC Nephrology*, **2017**, 18, 24	2.7	11
82	Intravenous iron: out of sight, out of mind. *Lancet Haematology,the*, **2018**, 5, e10-e12	14.6	10
81	Desmopressin use prior to renal transplant biopsy-does it fit?. *CKJ: Clinical Kidney Journal*, **2014**, 7, 602-4	4.5	10
80	Renal anemia: comparing current Eastern and Western European management practice (ORAMA). *Renal Failure*, **2008**, 30, 267-76	2.9	10
79	Individualizing target haemoglobin concentrations--tailoring treatment for renal anaemia. *Nephrology Dialysis Transplantation*, **2001**, 16 Suppl 7, 9-14	4.3	10
78	Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial?. *Clinical Nephrology*, **2019**, 91, 237-245	2.1	9
77	Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up. *Nephrology Dialysis Transplantation*, **2010**, 25, 914-9	4.3	9
76	Obesity and recovery from acute kidney injury (Ob AKI): a prospective cohort feasibility study. *BMJ Open*, **2019**, 9, e024033	3	8
75	Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. *Journal of Blood Medicine*, **2017**, 8, 155-163	2.3	8
74	Cognitive-behavioural therapy (CBT) for renal fatigue (BReF): a feasibility randomised-controlled trial of CBT for the management of fatigue in haemodialysis (HD) patients. *BMJ Open*, **2018**, 8, e020842	3	8
73	Effect of computer-assisted European Best Practice Guideline implementation on adherence and target attainment: ORAMA results. *Journal of Nephrology*, **2009**, 22, 662-74	4.8	8
72	Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome. *Journal of General Internal Medicine*, **2016**, 31, 353-6	4	7
71	Treatment of anaemia in end-stage renal disease: A double-edged iron sword?. *EBioMedicine*, **2019**, 40, 31-32	8.8	7
70	New data on the safety of IV iron-but why the discrepancy with FIND-CKD?. *Kidney International*, **2015**, 88, 1445-1446	9.9	7
69	Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study. *Current Medical Research and Opinion*, **2010**, 26, 2543-52	2.5	7

68	Should the hematocrit be normalized in dialysis and in pre-ESRD patients?. *Blood Purification*, **2001**, 19, 157-67	3.1	7
67	A prospective study of fatigue trajectories among in-centre haemodialysis patients. *British Journal of Health Psychology*, **2020**, 25, 61-88	8.3	7
66	SP311A MODEL TO PREDICT HAEMATOPOIETIC NON-RESPONSE TO ORAL IRON IN PATIENTS WITH NON-DIALYSIS DEPENDENT CKD (ND-CKD): AN ANALYSIS FROM THE FIND-CKD TRIAL. *Nephrology Dialysis Transplantation*, **2016**, 31, i193-i194	4.3	7
65	Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. *Annals of Medicine*, **2021**, 53, 274-285	1.5	7
64	Does Intragastric Balloon Treatment for Obesity in Chronic Kidney Disease Heighten Acute Kidney Injury Risk?. *American Journal of Nephrology*, **2016**, 44, 411-418	4.6	6
63	Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres. *Current Medical Research and Opinion*, **2009**, 25, 2971-6	2.5	6
62	How to optimise anaemia therapy in peritoneal dialysis patients. *Contributions To Nephrology*, **2006**, 150, 202-213	1.6	6
61	Experience With Intravenous Iron in Nephrology. *Seminars in Hematology*, **2006**, 43, S9-S12	4	6
60	Hematide□a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).. *Blood*, **2005**, 106, 3532-3532	2.2	6
59	CREATE: new strategies for early anaemia management in renal insufficiency. *Nephrology Dialysis Transplantation*, **2003**, 18 Suppl 2, ii13-6	4.3	6
58	Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease. *American Journal of Nephrology*, **2020**, 51, 493-500	4.6	5
57	Intravenous iron therapy in non-dialysis CKD patients. *Nephrology Dialysis Transplantation*, **2014**, 29, 717-29	4.3	5
56	The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. *BMC Nephrology*, **2017**, 18, 117	2.7	5
55	Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure. *Croatian Medical Journal*, **2015**, 56, 531-41	1.6	5
54	Serum erythropoietin levels may be inappropriately low in the acute neuropsychiatric porphyrias. *Clinica Chimica Acta*, **2002**, 317, 93-100	6.2	5
53	Higher target haemoglobin level and early anaemia treatment: different or complementary concepts?. *Nephrology Dialysis Transplantation*, **2000**, 15 Suppl 3, 3-7	4.3	5
52	Optimizing erythropoietin therapy. *Current Opinion in Hematology*, **1999**, 6, 121-6	3.3	5
51	SO036MOLIDUSTAT INCREASES HAEMOGLOBIN IN ERYTHROPOIESIS STIMULATING AGENTS (ESA)-NAIVE ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (CKD-ND). *Nephrology Dialysis Transplantation*, **2016**, 31, i16-i16	4.3	5

50	Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe. *American Journal of Kidney Diseases*, **2007**, 50, 358-61	7.4	4
49	Erythropoietin treatment in the neuropsychiatric porphyrias. *Clinica Chimica Acta*, **2003**, 338, 61-6	6.2	4
48	Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?. *Nephrology Dialysis Transplantation*, **2005**, 20 Suppl 8, viii18-21	4.3	4
47	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. *Kidney International*, **2021**, 100, 1101-1111	9.9	4
46	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. *Health Technology Assessment*, **2021**, 25, 1-52	4.4	4
45	The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1345-1355	4.5	4
44	Randomized Trial-PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis. *Kidney International Reports*, **2021**, 6, 2159-2170	4.1	4
43	Erythropoietin and renal failure. *Psychophysiology*, **2003**, 2, 459-64		4
42	Biosimilar epoetins. *Nephrology Dialysis Transplantation*, **2009**, 24, 1698-9; author reply 1699-700	4.3	3
41	Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial. *Trials*, **2007**, 8, 35	2.8	3
40	Optimal Iron Management in Patients Receiving Erythropoietin Therapy. *Seminars in Dialysis*, **2007**, 11, 10-13	2.5	3
39	Metabolic adjuvants to erythropoietin therapy. *Mineral and Electrolyte Metabolism*, **1999**, 25, 357-64		3
38	Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. *Nephrology Dialysis Transplantation*, **2021**,	4.3	3
37	Iron Treatment Strategies in Nondialysis CKD. *Seminars in Nephrology*, **2016**, 36, 99-104	4.8	3
36	Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. *Advances in Therapy*, **2020**, 37, 1960-2002	4.1	3
35	Preoperative intravenous iron for anaemia in elective major open abdominal surgery: the PREVENTT RCT. *Health Technology Assessment*, **2021**, 25, 1-58	4.4	3
34	SP334IRON REGULATION BY MOLIDUSTAT, BAY 85-3934, A DAILY ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR IN PATIENTS WITH CHRONIC KIDNEY DISEASE. *Nephrology Dialysis Transplantation*, **2018**, 33, i457-i457	4.3	2
33	Peginesatide for anemia in chronic kidney disease. *New England Journal of Medicine*, **2013**, 368, 1553-4	59.2	2

32	Nomenclature in nephrology: preserving 'renal' and 'nephro' in the glossary of kidney health and disease. *Journal of Nephrology*, **2021**, 34, 639-648	4.8	2
31	Feasibility Trial of Cognitive Behavioral Therapy for Fatigue in Hemodialysis (BReF Intervention). *Journal of Pain and Symptom Management*, **2021**, 61, 1234-1246.e5	4.8	2
30	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. *Cardiovascular Research*, **2021**,	9.9	2
29	Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. *American Journal of Therapeutics*, **2018**, 25, e670-e674	1	2
28	Reliability and validity of the five-repetition sit-to-stand test in adult kidney transplant recipients. *International Journal of Therapy and Rehabilitation*, **2018**, 25, 158-166	0.4	2
27	Intravenous Iron Use in the Care of Patients with Kidney Disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 1528-1530	6.9	1
26	Supplemental iron via dialysate: a novel mode of delivery for hemodialysis patients. *Kidney International*, **2015**, 88, 946-9	9.9	1
25	Iron therapy for managing anaemia in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2018**, 27, 358-363	3.5	1
24	Over 5 years of darbepoetin alfa: two case histories. *Expert Opinion on Pharmacotherapy*, **2004**, 5, 951-4	4	1
23	Darbepoetin Alfa: A Viewpoint by Iain C. Macdougall. *Drugs*, **2001**, 61, 2105-2106	12.1	1
22	Iron Supplementation: What's New?. *Blood*, **2017**, 130, SCI-43-SCI-43	2.2	1
21	The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia.. *Kidney International Reports*, **2022**, 7, 322-326	4.1	1
20	MP415EFFECT OF INTRAVENOUS IRON THERAPY WITH FERRIC CARBOXYMALTOSE ON OUTCOMES IN IRON-DEFICIENT PATIENTS WITH RENAL DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF FOUR RANDOMIZED, DOUBLE-BLIND TRIALS. *Nephrology Dialysis Transplantation*, **2017**, 32, iii581-iii581	4.3	1
19	Authors' Reply. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 1654	12.7	1
18	P0858A MULTICENTRE PROSPECTIVE DOUBLE BLIND RANDOMISED CONTROLLED TRIAL OF INTRAVENOUS IRON IN IRON DEFICIENT BUT NOT ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE ON FUNCTIONAL STATUS. *Nephrology Dialysis Transplantation*, **2020**, 35,	4.3	1
17	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. *Nephrology Dialysis Transplantation*, **2021**, 36,	4.3	1
16	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. *JACC: Heart Failure*, **2021**, 9, 518-527	7.9	1
15	Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.. *Kidney360*, **2021**, 2, 1761-1769	1.8	1

14	The ASCEND-ND trial: Study design and participant characteristics. *Nephrology Dialysis Transplantation*, **2021**,	4.3	1
13	Iron Deficiency in CKD Without Concomitant Anemia. *Kidney International Reports*, **2021**, 6, 2752-2762	4.1	0
12	Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial.. *Scientific Reports*, **2022**, 12, 6853	4.9	0
11	Behavioural change and exercise therapy for patients with CKD. *Journal of Kidney Care*, **2017**, 2, 58-65	0.1	
10	A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia". *American Journal of Hematology*, **2018**, 93, E232-E233	7.1	
9	Renal rehabilitation: the benefits, barriers and exercise options. *Journal of Renal Nursing*, **2014**, 6, 29-33		
8	Unusual presentation of aortic dissection with bilateral testicular pain and rapidly deteriorating renal function. *Urology*, **2014**, 83, 989-91	1.6	
7	The authors reply. *Kidney International*, **2014**, 86, 211	9.9	
6	Erythropoietic therapy: time for some changes. *Journal of Renal Nursing*, **2011**, 3, 6-9		
5	Once-weekly erythropoietic therapy: is there a difference between the available preparations?. *Nephrology Dialysis Transplantation*, **2003**, 18, 36viii-36	4.3	
4	Renal cell carcinoma in kidney transplant recipients at Guy's and King's College Hospital (UK) between 1987-2018.. *Journal of Clinical Oncology*, **2019**, 37, e16066-e16066	2.2	
3	Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents. *Blood*, **2014**, 124, 3516-3516	2.2	
2	Fatal and Serious Anaphylaxis Following Peginesatide Administration. *Blood*, **2013**, 122, 5612-5612	2.2	
1	SP555IMPROVING ANAEMIA THERAPY IN HAEMODIALYSIS PATIENTS: RESULTS OF A MULTICENTRE CLINICAL AUDIT. *Nephrology Dialysis Transplantation*, **2016**, 31, i277-i277	4.3	